Hagen Steven R 4

Accession 0001638599-17-000877

CIK 0001065087other

Filed

Sep 4, 8:00 PM ET

Accepted

Sep 5, 4:28 PM ET

Size

24.3 KB

Accession

0001638599-17-000877

Form 4

Period: 2017-08-31

VP Pharmaceutical Dev & Mfg

Transactions

Disposition to Issuer
Common Stock
2017-08-31$21.75/sh−43,655$949,496→ 0 total
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$15.76/sh−3,750$59,100→ 0 total
Exercise: $5.99Exp: 2023-01-31→ Common Stock (3,750 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$11.32/sh−20,000$226,400→ 0 total
Exercise: $10.43Exp: 2024-02-04→ Common Stock (20,000 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$5.98/sh−22,889$136,876→ 0 total
Exercise: $15.77Exp: 2026-02-04→ Common Stock (22,889 underlying)
Award
Common Stock
2017-08-31+3,138→ 43,655 total
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$15.76/sh−7,500$118,200→ 0 total
Exercise: $5.99Exp: 2023-01-31→ Common Stock (7,500 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$15.76/sh−3,750$59,100→ 0 total
Exercise: $5.99Exp: 2023-01-31→ Common Stock (3,750 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$18.82/sh−3,750$70,575→ 0 total
Exercise: $2.93Exp: 2022-02-17→ Common Stock (3,750 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$4.70/sh−16,280$76,516→ 0 total
Exercise: $17.05Exp: 2025-03-02→ Common Stock (16,280 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2017-08-31$3.34/sh−29,412$98,236→ 0 total
Exercise: $18.41Exp: 2027-02-08→ Common Stock (29,412 underlying)

Footnotes (2)

[F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
[F2]Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.

Documents

1 file

ALBANY MOLECULAR RESEARCH INC

CIK 0001065087

Entity typeother